Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake

E-ISSN： 1468-1293|16|10|599-607

ISSN： 1464-2662

Source： HIV MEDICINE, Vol.16, Iss.10, 2015-11, pp. : 599-607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

HIV MEDICINE, Vol. 16, Iss. 5, 2015-05 ,pp. : 297-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

HIV MEDICINE, Vol. 19, Iss. 3, 2018-03 ,pp. : 227-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

IFN‐λ gene polymorphisms as predictive factors in chronic hepatitis C treatment‐naive patients without access to protease inhibitors

JOURNAL OF MEDICAL VIROLOGY, Vol. 87, Iss. 10, 2015-10 ,pp. : 1702-1715

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co‐infected with HIV

JOURNAL OF MEDICAL VIROLOGY, Vol. 87, Iss. 9, 2015-09 ,pp. : 1549-1557

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel

By Chatel-Chaix Laurent Baril Martin Lamarre Daniel

Viruses, Vol. 2, Iss. 8, 2010-08 ,pp. : 1752-1765

MDPI

Access to resources Recommend Favorite